Medtronic Cited For Late Postmarket Report; First “522” Action Under FDAMA
This article was originally published in The Gray Sheet
Executive Summary
An FDA 1warning letter sent to Medtronic Sept. 27 is the agency's first enforcement action under its 1997 powers to compel device makers to collect specified postmarket surveillance data
You may also be interested in...
Small Samples, Protocol Delays Mar FDA’s Use Of Postapproval Studies
Small sample sizes and delays in reaching protocol agreements are hindering FDA’s ability to use postapproval study data to track device performance, says a study in JAMA Internal Medicine.
Feds Try To Pave Path For Frustrated Pediatric Device Innovators
The National Institutes of Health and other government agencies will submit plans to Congress next month on how to encourage the development of medical devices designed specifically with children in mind. Innovators say having a clear path could make a difference, but the challenges of getting support for a pediatric project all the way to market remain steep
Feds Try To Pave Path For Frustrated Pediatric Device Innovators
The National Institutes of Health and other government agencies will submit plans to Congress next month on how to encourage the development of medical devices designed specifically with children in mind. Innovators say having a clear path could make a difference, but the challenges of getting support for a pediatric project all the way to market remain steep